Coagulation factor viia recombinant human
Voncento (coagulation factor viia recombinant human) is an unknown pharmaceutical. Coagulation factor viia recombinant human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hemophilia a | EFO_0007267 | D006467 | D66 |
| hemophilia b | — | D002836 | D67 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 11 | 20 | 6 | 3 | 17 | 56 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 18 | 8 | 12 | 5 | 15 | 55 |
| Hemostatic disorders | D020141 | — | — | 11 | 19 | 6 | 3 | 17 | 55 |
| Hemophilia b | D002836 | — | D67 | 13 | 6 | 8 | 4 | 10 | 39 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 5 | 14 | 5 | 2 | 9 | 35 |
| Postpartum hemorrhage | D006473 | — | O72 | — | — | — | 1 | 4 | 5 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral hemorrhage | D002543 | — | — | — | 7 | 2 | — | — | 9 |
| Wounds and injuries | D014947 | — | T14.8 | — | 3 | 2 | — | 1 | 6 |
| Cardiac surgical procedures | D006348 | — | — | — | 1 | 1 | — | — | 2 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | 1 | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
| Hemorrhagic stroke | D000083302 | — | — | — | — | 1 | — | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | 1 | — | — | 1 |
| Burns | D002056 | — | T30.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Factor vii deficiency | D005168 | HP_0008169 | D68.2 | 2 | 1 | — | — | 2 | 4 |
| Thrombasthenia | D013915 | — | D69.1 | 1 | 1 | — | — | 3 | 4 |
| Hematoma | D006406 | EFO_0010680 | — | — | 1 | — | — | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | — | — | — | 2 |
| Coronary disease | D003327 | — | — | — | 1 | — | — | — | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | — | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | — | — | — | 1 |
| Dengue | D003715 | — | A90 | — | 1 | — | — | — | 1 |
| Severe dengue | D019595 | — | A91 | — | 1 | — | — | — | 1 |
| Viral hemorrhagic fevers | D006482 | — | A99 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Hemorrhagic disorders | D006474 | — | D69.9 | 1 | — | — | — | 1 | 2 |
| Hemostasis | D006487 | — | — | 2 | — | — | — | — | 2 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 1 | 1 |
| Cardiopulmonary bypass | D002315 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhagic shock | D012771 | — | — | — | — | — | — | 1 | 1 |
| Traumatic brain hemorrhage | D020201 | — | — | — | — | — | — | 1 | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 1 | 1 |
| Contusions | D003288 | — | T14.8 | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
| Brain contusion | D000070624 | — | — | — | — | — | — | 1 | 1 |
| Factor xi deficiency | D005173 | — | D68.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Coagulation factor viia recombinant human |
| INN | eptacog beta (activated) |
| Description | Voncento (coagulation factor viia recombinant human) is an unknown pharmaceutical. Coagulation factor viia recombinant human was first approved as Voncento on 2013-08-12. It has been approved in Europe to treat hemophilia a and von willebrand diseases. |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297869 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | AC71R787OV (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 120 documents
View more details
Safety
Black-box Warning
Black-box warning for: Novoseven, Sevenfact
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
834 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use